Projected prevalence of cirrhosis and overt hepatic encephalopathy in the United States, 2021-2030 (plenary session)

Wong, R.

Rifaximin monotherapy has significantly reduced the risk of overt hepatic encephalopathy recurrence versus lactulose monotherapy in patients with cirrhosis and a history of previous episode(s): a post hoc analysis of randomized trials

Bajaj JS, et al.

Healthcare costs in patients with hepatic encephalopathy receiving rifaximin-α treatment in the IMPRESS II study

Buxton A, et al.

Systematic undercounting of overt hepatic encephalopathy hospitalizations identified by using hospital-administered medication data [abstract 3108-A; page 1414]

Jesudian A, et al.

Fifteen-year trends in the prevalence of decompensated cirrhosis and overt hepatic encephalopathy among Medicare beneficiaries in the United States (2006–2020) [abstract 3076-A; page 1389]

Wong RJ, et al.

Regional variations across the United States in the prevalence of overt hepatic encephalopathy and rifaximin utilization among commercially and Medicare insured adults [abstract 3100-A; page 1408]

Wong RJ, et al.

Comparative pharmacokinetics of rifaximin 550 mg and 200 mg oral tablets: one is not like the other

Heimanson Z, et al.

Rifaximin plus lactulose is more effective than lactulose alone for the prevention of overt hepatic encephalopathy in patients with or without diabetes

Bajaj JS, et al.

Impact of updated mortality estimates on the cost-effectiveness of rifaximin for the treatment of patients with overt hepatic encephalopathy

Bhattacharyya S, et al.

Real-world trends in hospitalizations for hepatic encephalopathy and associated costs among adults in the United States

Wong R, et al.

Long term care services use among Medicare patients treated with rifaximin for overt hepatic encephalopathy

Gagnon-Sanschagrin P, et al.

Impact of rifaximin use during the 30-day post-discharge period following an overt hepatic encephalopathy hospitalization on healthcare utilization and costs

Jesudian A, et al.

Perception of moderate to high risk factors for developing primary overt hepatic encephalopathy across physician specialties in the United States

Jesudian A, et al.

Rifaximin plus lactulose is more efficacious than lactulose alone for the prevention of overt hepatic encephalopathy (OHE) in patients with or without ascites

Kowdley KV, et al.

Real-world trends in the prevalence of cirrhosis and rates of hepatic encephalopathy among adults in the United States from 2006–2020

Wong R, et al.

Identification of overt hepatic encephalopathy precipitating factors: a pooled analysis of 3 clinical trials of rifaximin plus lactulose [encore]

Jesudian AB, et al.

Rifaximin plus lactulose versus lactulose alone for reducing the risk of overt hepatic encephalopathy recurrence: a pooled subgroup analysis

Sanyal AJ, et al.

Identification of overt hepatic encephalopathy precipitating factors: a pooled analysis of 3 clinical trials of rifaximin plus lactulose

Jesudian AB, et al.

Rifaximin plus lactulose is more efficacious than lactulose alone for risk reduction of overt hepatic encephalopathy recurrence: a subgroup analysis by viral or alcohol cirrhosis etiology  [Encore]

Bajaj JS, et al.

Rifaximin plus lactulose is more efficacious than lactulose alone for risk reduction of overt hepatic encephalopathy (OHE) recurrence: a subgroup analysis by viral or alcohol cirrhosis etiology

Bajaj JS, et al.

Precipitating factors of overt hepatic encephalopathy occurrence: an analysis of 3 rifaximin clinical trials

Flamm SL, et al.

Lack of colonic microbial cross-resistance to other antibiotics in patients treated with rifaximin alone versus rifaximin plus lactulose for reducing the risk of overt hepatic encephalopathy recurrence

Frenette CT, et al.

Rifaximin and lactulose combination therapy versus lactulose alone for prevention of overt hepatic encephalopathy recurrence: a pooled analysis of two randomized trials [Encore]

Werner KT, et al.

Rifaximin and lactulose combination therapy versus lactulose alone for prevention of overt hepatic encephalopathy recurrence: a pooled analysis of two randomized trials [Encore]

Bajaj JS, et al.

Lactulose withdrawal can potentiate breakthrough overt hepatic encephalopathy in patients controlled with rifaximin plus lactulose therapy: a post hoc analysis of a randomized controlled trial

Bajaj JS, et al.

Lactulose withdrawal can potentiate breakthrough overt hepatic encephalopathy in patients controlled with rifaximin plus lactulose therapy: a post hoc analysis of a randomized controlled trial  [Encore]

Bajaj JS, et al.

Rifaximin and lactulose combination therapy versus lactulose alone for prevention of overt hepatic encephalopathy recurrence: a pooled analysis of two randomized trials  [Encore]

Bajaj JS, et al.

Efficacy and safety of rifaximin treatment for reducing the risk of overt hepatic encephalopathy by baseline hepatic impairment  [Encore]

Flamm SL, et al.

Rifaximin and lactulose combination therapy versus lactulose alone for prevention of overt hepatic encephalopathy recurrence: a pooled analysis of two randomized trials

Bajaj JS, et al.

Efficacy and safety of rifaximin treatment for reducing the risk of overt hepatic encephalopathy by baseline hepatic impairment

Flamm SL, et al.

Economic burden of overt hepatic encephalopathy and pharmacoeconomic impact of rifaximin

Neff G, et al.

Assessment of potential impact of demographic and baseline disease characteristics on rifaximin monotherapy versus lactulose combination therapy for the prevention of overt hepatic encephalopathy (OHE) recurrence

Flamm SL, et al.

Rifaximin for the prevention of complications of cirrhosis

Flamm SL, et al.

Genomic characterization of stool microbiota with rifaximin monotherapy versus lactulose combination therapy for prevention of overt hepatic encephalopathy (HE) recurrence

DuPont HL, et al.

Changes in antimicrobial susceptibility of fecal bacteria during rifaximin treatment for the prevention of overt hepatic encephalopathy (HE) recurrence

DuPont HL, et al.

Cost-effectiveness of rifaximin treatment in patients with hepatic encephalopathy

Bozkaya D, et al.

Utility of the Hepatic Encephalopathy Scoring Algorithm (HESA) for diagnosing hepatic encephalopathy in a randomized, controlled trial of rifaximin vs placebo

Hassanein T, et al.

Efficacy and tolerability of rifaximin in hepatitis C patients with recurrent hepatic encephalopathy

Neff GW, et al.